Urothelial carcinoma(UC),as a common malignant tumor of the urinary system,has an in-creasing inumber of patients.Some patients have developed into inoperable locally advanced or distant meta-static UC(la/mUC)at the initial treatment.At present,the standard treatment scheme is platinum-based chemotherapy,but the adverse reactions and therapeutic effects are not ideal.In recent years,antibody-drug conjugate combined with immune checkpoint inhibitors has gradually become a new focus of cancer precision medicine research,bringing new treatment options for these patients.Currently,there are many clinical trials in this field,and the purpose of this article was to provide a comprehensive review of the recent research pro-gress.
维普
万方数据